

cOplete, Mini

Protease Inhibitor Cocktail Tablets provided in *EASYpack*

For the complete inhibition of proteases during extractions from animal and plant tissues or cells, yeast and bacteria

Cat. No. 04 693 124 001

30 tablets

 **Do not eat**

 **Version 04**

Content version: September 2014

Store at +2 to +8°C

1. What this Product Does

1.1 Properties

cOplete, Mini tablets inhibit a broad spectrum of serine, cysteine and metalloproteases as well as calpains.

Due to the optimized composition of the tablets they show excellently inhibition effects and are therefore very well suited for the protection of proteins isolated from animal tissues, plants, yeast and bacteria. cOplete, Mini contains both irreversible and reversible protease inhibitors.

1.2 Contents

30 individually packed cOplete Protease Inhibitor Cocktail Tablets in foil blisters. Each tablet is sufficient for a volume of 10 ml solution.

1.3 Stability

- The tablets are stable at +2 to +8°C, stored dry, until expiration date.
- The stock solution is stable for 1–2 weeks, stored at +2 to +8°C, or at least for 12 weeks at –15 to –25°C.

1.4 Application

Used for the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.

cOplete, Mini contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOplete to all stock buffers and solutions normally protected with protease inhibitors and not only during the initial purification steps.

cOplete, Mini contains EDTA (3.7 mg/tablet yield 1 mM solution of EDTA in 10 ml). Therefore, the extraction buffer should not contain divalent cations like Ca^{2+} , Mg^{2+} or Mn^{2+} ; otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (immobilized metal-chelate affinity chromatography), e.g. Poly-His tagged recombinant proteins, EDTA has to be eliminated (e.g. by dialysis) prior to the chromatography.

Alternatively, the product cOplete, Mini, EDTA-free can be used (see table "Ordering Information"). These tablets are identical to cOplete, with the only difference that no EDTA or other chelating agent are present.

2. How to Use this Product

2.1 Handling

Carefully push the tablet through the foil packaging using the base of your thumb (and not your finger nail) to prevent the breakage of tablets.

 **Do not eat the tablets.**

2.2 Preparation of Working Solutions

One tablet cOplete, Mini is sufficient for the inhibition of the proteolytic activity in 10 ml extraction solution. If very high proteolytic activity is present, one tablet should be used for 7 ml extraction buffer. The tablets can be added directly to the extraction medium. Alternatively a stock solution (7 × conc.) can be prepared.

If it is necessary to inhibit proteolytic activity in a larger volume we recommend to use cOplete (1 tablet for 50 ml extraction solution, see "Ordering Information"). The composition of the cOplete tablet is identical to the cOplete, Mini tablet, therefore comparable results are achieved with both product types.

2.3 Stock solution (7 × conc.)

Dissolve one tablet cOplete, Mini in 1.5 ml redist. H_2O or in 100 mM phosphate buffer, pH 7.0.

3. Results

In extracts from animal tissues mainly serine, cysteine and metalloproteases are found; in plant extracts serine and cysteine proteases dominate. For bacterial extracts serine and metalloproteases are typical (1). cOplete, Mini tablets inhibit efficiently serine, cysteine and metalloproteases in a broad range.

Occasionally, aspartic proteases ("acid proteases") can interfere upon isolations from animal tissues. These proteases, however, exhibit pronounced activities only at low pH values. If extraction or single isolation steps have to be performed at this pH range the addition of pepstatin* is recommended to inhibit aspartic protease activity as a precaution.

Typical values for the inhibition of different proteases and protease mixtures by cOplete, Mini are shown in table 1.

Protease resp. protease mixture	Enzyme concentration (mg/ml)	pH-value	% inhibition after immediate addition to the protease	% inhibition after 60 min incubation (protease + cOplete) at +15 to +25°C
Pancreas-extract	0.02	7.8	85%	96%
Pronase	0.005	7.8	92%	98%
Thermolysin	0.0005	7.8	98%	98%
Chymotrypsin	0.0015 0.003	7.8 7.8	85% 90%	93% 93%
Papain	0.33	7.8	66%	77%

Table 1: Inhibition of different proteases by cOplete Protease Inhibitor Tablets.

One cOplete, Mini tablet was added per 10 ml incubation solution. Proteolytic activity was determined with the Roche Diagnostics Universal Protease Substrate (casein, resorufin-labeled*). When extractions or single-step isolations are necessary in the acid pH range, simply include pepstatin* along with cOplete, Mini tablets to ensure aspartic (acid) protease inhibition. All experiments were performed at room temperature.

* available from Roche Diagnostics

4. Additional Information on this Product

4.1 Absorption

A solution of 1 tablet cOmplete, Mini dissolved in 10 ml H₂O has an absorption of 0.08 at 280 nm.

4.2 Quality Control

The inhibitory power of cOmplete, Mini has been demonstrated with many proteases and protease mixtures. In these experiments drastically higher concentrations of proteases were used compared to the concentration usually present in extracts (see table 1). The inhibitory activity of each lot is tested with a concentrated pancreas extract and a concentrated pronase solution. Thereby, the proteolytic activities are typically inhibited by 95% after one hour (detection with universal protease substrate casein, resorufin-labeled*).

4.3 Reference

- 1 North, M.J. (1969) in: Proteolytic Enzymes - A Practical Approach (Beynon, P.J. & Bond, J.S. eds.), IRL press Oxford, pp. 117-119.

5. Supplementary Information

5.1 Ordering Information

Roche Diagnostics offers a large selection of reagents and systems for life science research. For a complete overview of related products and manuals, please visit and bookmark our homepage www.lifescience.roche.com

cOmplete Protease Inhibitor Cocktail Tablets in *EASYpacks*:

Product	Pack size	Cat. No.
cOmplete	20 tablets in foil blisters (for 50 ml each)	04 693 116 001
cOmplete, Mini	30 tablets in foil blisters (for 10 ml each)	04 693 124 001
cOmplete, EDTA-free	20 tablets in foil blisters (for 50 ml each)	04 693 132 001
cOmplete, Mini, EDTA-free	30 tablets in foil blisters (for 10 ml each)	04 693 159 001

cOmplete Protease Inhibitor Cocktail Tablets in glass vials:

Product	Pack size	Cat. No.
cOmplete	20 tablets in a glass vial (for 50 ml each)	11 697 498 001
	3 × 20 tablets in a glass vial (for 50 ml each)	11 836 145 001
cOmplete, Mini	25 tablets in a glass vial (for 10 ml each)	11 836 153 001
cOmplete, EDTA-free	20 tablets in a glass vial (for 50 ml each)	11 873 580 001
	3 × 20 tablets in a glass vial (for 50 ml each)	05 056 489 001
cOmplete, Mini, EDTA-free	25 tablets in a glass vial (for 10 ml each)	11 836 170 001

cOmplete ULTRA Protease Inhibitor Cocktail Tablets:

Product	Pack size	Cat. No.
cOmplete ULTRA, Mini, EDTA-free, <i>EASYpack</i>	30 tablets in foil blisters (for 10 ml each)	05 892 791 001
cOmplete ULTRA, EDTA-free, glass vials	2 × 10 tablets in glass vials (for 50 ml each)	05 892 953 001
	6 × 10 tablets in glass vials (for 50 ml each)	06 538 282 001
cOmplete ULTRA, Mini, with EDTA, <i>EASYpack</i>	30 tablets in foil blisters (for 10 ml each)	05 892 970 001
cOmplete ULTRA, with EDTA, glass vials	2 × 10 tablets in glass vials (for 50 ml each)	05 892 988 001
	6 × 10 tablets in glass vials (for 50 ml each)	06 538 304 001

PhosSTOP Phosphatase Inhibitor Cocktail Tablets:

Product	Pack size	Cat. No.
PhosSTOP	10 tablets in foil blisters (for 10 ml each)	04 906 845 001
PhosSTOP	20 tablets in foil blisters (for 10 ml each)	04 906 837 001

cOmplete His-Tag Purification:

Product	Pack size	Cat. No.
cOmplete His-Tag	25 ml settled resin volume	05 893 682 001
Purification Resin	200 ml settled resin volume	05 893 801 001

5.2 Changes to Previous Version

- Editorial changes
- Ordering Information updated

5.3 Trademarks

COMPLETE and PHOSSTOP are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

5.4 Regulatory Disclaimer

For life science research only. Not for use in diagnostic procedures.

Contact and Support

To ask questions, solve problems, suggest enhancements and report new applications, please visit our [Online Technical Support Site](http://www.lifescience.roche.com).

To call, write, fax, or email us, visit www.lifescience.roche.com, and select your home country. Country-specific contact information will be displayed.



Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany